NCT03044964 - Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions

Angina

Interventions

DRUG

Ranolazine

Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.

DRUG

Placebo

Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.

Trial Locations (1)

38671

RECRUITING

Stern Cardiovascular Foundation, Inc, Southaven